Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Leila Siavoshinia"'
Publikováno v:
Iranian Journal of Allergy, Asthma and Immunology, Vol 18, Iss 5 (2019)
Targeting of cancerous cells with a high level of human epidermal growth factor receptor 2 (HER2) expressions by drug immunoconjugates is a new approach for specific delivery of chemotherapeutic agents. Our previous work indicated that idarubicin-ZHE
Externí odkaz:
https://doaj.org/article/a919d7e6fd984bf1a0946b173d6f417a
Autor:
Bahman Moradipoodeh, Majid Zeinali, Leila Siavoshinia, Aminollah Pourshohod, Ghorban Mohammadzadeh, Mahdie Koushki, Mostafa Jamalan
Publikováno v:
Iranian Journal of Pathology, Vol 16, Iss 2, Pp 109-118 (2020)
Background & objectives: Overexpression of human epidermal growth factor receptor 2 (HER2) causes cell transformation and development of various types of malignancies. Idarubicin is an effective anti-neoplastic drug but specific delivery of it to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::591ee82de9a2846d7a3fe32482bb9dc8
https://ijp.iranpath.org/article_239970_77351c9e419599a2a56c503337b57117.pdf
https://ijp.iranpath.org/article_239970_77351c9e419599a2a56c503337b57117.pdf
Autor:
Leila, Siavoshinia, Alireza, Kheirollah, Majid, Zeinali, Ebrahim, Barzegari, Mostafa, Jamalan
Publikováno v:
International immunopharmacology. 101
Due to the high affinity for binding to target molecules and also other unique attributes, affibodies have a great potential to be used in immunotherapeutic and diagnostic approaches. However, the possibility of undesirable immune response is still a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f5c69903334bb7afa9ddd2a436c706b0
https://pubmed.ncbi.nlm.nih.gov/34857479
https://pubmed.ncbi.nlm.nih.gov/34857479
Autor:
Leila, Siavoshinia, Mostafa, Jamalan, Majid, Zeinali, Aminollah, Pourshohod, Mahdie, Koushki, Bahman, Moradipoodeh, Ghorban, Mohammadzadeh
Publikováno v:
Iranian Journal of Pathology
Background & Objective: Overexpression of human epidermal growth factor receptor 2 (HER2) causes cell transformation and development of various types of malignancies. Idarubicin is an effective anti-neoplastic drug but its specific delivery to the ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::38dc0f582919b1fbded7fed80d817092
https://pubmed.ncbi.nlm.nih.gov/33936221
https://pubmed.ncbi.nlm.nih.gov/33936221
Publikováno v:
Iranian Journal of Allergy, Asthma and Immunology, Vol 18, Iss 5 (2019)
Targeting of cancerous cells with a high level of human epidermal growth factor receptor 2 (HER2) expressions by drug immunoconjugates is a new approach for specific delivery of chemotherapeutic agents. Our previous work indicated that idarubicin-ZHE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edfb818f4b90a8832a403b6d6ffd0778
https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2075
https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2075